Fib target 15 plus Fundamentals OutstandingThis is a rocket ship firing on all cylinders.
Jazz acquisition is worth 1.9 billion dollars alone.
0%
0%
0%
0%
0%
About Zymeworks Inc
Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Kenneth Harry Galbraith
Website
zymeworks.com
Headquarters
Middletown
Employees
294
Founded
2003
ISIN
US98985Y1082
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab’s unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
ZYME - broke up from baseZYME peaked @ 59 in Jan2021 and had been generally on the downtrend since. It began to bottom around Feb 2022 (after a 90% plunge!) and had been consolidating in a sideway range until the 200 day MA began to come down and flatten out.
Today it gapped strongly out of this range high of 9.28, a pos
See all ideas
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
